Asco 2025 · Posters ·
Cáncer de Mama
Asco 2025 · Posters ·
Cáncer de Mama
Molecular and immune profiling of breast cancer from pregnancy to postpartum: Insights into the tumour-immune landscape during breastfeeding from GEICAM EMBARCAM study.
Cost-effectiveness of HER2/neu 655 genotyping in managing trastuzumab-induced cardiotoxicity risk in HER2-positive breast cancer patients.
Effect of a multidisciplinary intervention based on a supervised training program on cardiovascular risk and quality of life in early stage breast cancer patients.
HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.
TROP2 overexpression as predictor of outcome in patients with early triple-negative breast cancer. Exploratory analysis from the GEICAM_CIBOMA trial.
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.
ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.
Acceso
